Literature DB >> 18830723

Treatment of localized oral MALT lymphoma by rituximab: a case report.

Kenji Yamagata1, Kojiro Onizawa, Hiroshi Kojima, Hiroshi Yoshida.   

Abstract

INTRODUCTION: Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoma tissue (MALT) among intraoral malignant lymphomas is very rare. Moreover, no case of oral MALT lymphoma treated with monoclonal antibody therapy has been reported. DISCUSSION: We describe a case of MALT lymphoma arising in an 87-year-old Japanese woman under the buccal mucosa that was successfully treated with rituximab, a chimeric monoclonal antibody against the B cell-specific antigen CD20. Currently, 5 months after completing treatment, the patient is alive and has partial regression of the tumor.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18830723     DOI： 10.1007/s10006-008-0135-3

Source DB:  PubMed          Journal:  Oral Maxillofac Surg        ISSN： 1865-1550


  18 in total

1.  Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome.

Authors:  M Voulgarelis; U G Dafni; D A Isenberg; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  1999-08

2.  Marginal zone B-cell lymphoma of minor salivary gland representing tumor-forming amyloidosis of the oral cavity. A case report.

Authors:  Masaru Kojima; Shiro Sugihara; Misa Iijima; Takayuki Ono; Takashi Yoshizumi; Nobuhide Masawa
Journal:  J Oral Pathol Med       Date:  2006-05       Impact factor: 4.253

3.  Parotid MALT lymphoma in HIV infected children.

Authors:  P Corr; M Vaithilingum; R Thejpal; P Jeena
Journal:  J Ultrasound Med       Date:  1997-09       Impact factor: 2.153

4.  Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study.

Authors:  Alexandros Kolokotronis; Nikolaos Konstantinou; Ioannis Christakis; Phinelopi Papadimitriou; Apostolos Matiakis; Thomas Zaraboukas; Demetrios Antoniades
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2005-03

5.  Indolent behaviour of low-grade B-cell lymphoma of mucosa-associated lymphoid tissue involved in salivary glands, renal sinus and prostate.

Authors:  K Araki; Y Kubota; Y Iijima; H Suzuki; I Sasagawa; T Nakada; K Maeda; S Arai
Journal:  Scand J Urol Nephrol       Date:  1998-05

6.  Primary lymphoma of mucosa associated lymphoid tissue (MALT) in the parotid gland.

Authors:  A J Balm; P Delaere; F J Hilgers; R Somers; P Van Heerde
Journal:  Clin Otolaryngol Allied Sci       Date:  1993-12

7.  Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients.

Authors:  C Thieblemont; Y Bastion; F Berger; C Rieux; G Salles; C Dumontet; P Felman; B Coiffier
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

8.  Lymphomas of the oral cavity: histology, immunologic type, and incidence of Epstein-Barr virus infection.

Authors:  Charalambos C Solomides; Arthur S Miller; Robert A Christman; Jotica Talwar; Henry Simpkins
Journal:  Hum Pathol       Date:  2002-02       Impact factor: 3.466

9.  Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy.

Authors:  Catharina Wenzel; Wolfgang Fiebiger; Karin Dieckmann; Michael Formanek; Andreas Chott; Markus Raderer
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

10.  Multiple nodular lesions of the chin and oral mucosa in a patient with Sjögren's syndrome.

Authors:  C Stinchi; B M Piraccini; S Pileri; S Lorenzi; P Casavecchia; P A Fanti; A Tosti
Journal:  Eur J Dermatol       Date:  1998 Jul-Aug       Impact factor: 3.328
View more
  1 in total

1.  Primary MALT lymphoma of the upper lip mucosa: an exceptionally rare localisation.

Authors:  Pasquale Niscola; Massimiliano Palombi; Stefano Fratoni; Monika Malgorzata Trawinska; Laura Scaramucci; Micaela Ales; Andrea Tendas; Luca Cupelli; Alessio Perrotti; Paolo de Fabritiis
Journal:  Int J Hematol       Date:  2008-12-25       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.